Autor: |
Leuven JA, Havekes L, van der Kooij-Pontier HA, Starmans RJ, Jansen H, Bouwhuis-Hoogerwerf ML, de Pagter HA, Hessel LW |
Jazyk: |
angličtina |
Zdroj: |
Metabolism: clinical and experimental [Metabolism] 1984 Nov; Vol. 33 (11), pp. 1039-42. |
DOI: |
10.1016/0026-0495(84)90234-8 |
Abstrakt: |
Changes in circulating lipoproteins, which may be related to the risk for atherosclerotic vascular disease, were studied in a control group and in two groups of 24 or 26 women using different preparations of low-dose oral contraceptives for 3 months. One preparation contained 150 micrograms levo-norgestrel and 30 micrograms ethinylestradiol (Stediril-d 150/30); the other contained 750 micrograms lynestrenol and 37.5 micrograms ethinylestradiol (Ministat). No significant changes were found with either of the preparations in serum cholesterol or high density lipoprotein cholesterol (HDL-C) levels. Apolipoprotein A-II levels increased during Ministat treatment from 50.4 to 61.4 mg/dL and during Stediril-d 150/30 treatment from 52.7 to 58.9 mg/dL (both P less than 0.001). These changes differed significantly from each other (P less than 0.01). Apolipoprotein A-I levels increased significantly during use of Ministat only. Apolipoprotein B in low density lipoprotein increased by about 20% (P less than 0.001) in both groups. Post-heparin lipoprotein lipase activity did not change, but hepatic lipase activity decreased to the same extent in both groups (P less than 0.001). Reductions in post-heparin lipase activity were not correlated with increases in HLD-C. |
Databáze: |
MEDLINE |
Externí odkaz: |
|